

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

## Epstein-Barr Virus-Induced Genes: First Lymphocyte-Specific G Protein-Coupled Peptide Receptors

MARK BIRKENBACH,<sup>1</sup> KNUD JOSEFSEN,<sup>2</sup> RAMANA YALAMANCHILI,<sup>1</sup>  
GILBERT LENOIR,<sup>3</sup> AND ELLIOTT KIEFF<sup>1\*</sup>

*Departments of Medicine and of Microbiology and Molecular Genetics, \* Virology Program,  
Harvard University, 75 Francis Street, Boston, Massachusetts 02115<sup>1</sup>; The Bartholin  
Institute, Kommunehospitalet, 1399 Copenhagen K, Denmark<sup>2</sup>; and International  
Agency for Research Against Cancer, Lyon, France<sup>3</sup>*

Received 23 October 1992/Accepted 24 December 1992

Since Epstein-Barr virus (EBV) infection of Burkitt's lymphoma (BL) cells in vitro reproduces many of the activation effects of EBV infection of primary B lymphocytes, mRNAs induced in BL cells have been cloned and identified by subtractive hybridization. Nine genes encode RNAs which are 4- to >100-fold more abundant after EBV infection. Two of these, the genes for CD21 and vimentin, were previously known to be induced by EBV infection. Five others, the genes for cathepsin H, annexin VI (p68), serglycin proteoglycan core protein, CD44, and the myristylated alanine-rich protein kinase C substrate (MARCKS), are genes which were not previously known to be induced by EBV infection. Two novel genes, EBV-induced genes 1 and 2 (EBI 1 and EBI 2, respectively) can be predicted from their cDNA sequences to encode G protein-coupled peptide receptors. EBI 1 is expressed exclusively in B- and T-lymphocyte cell lines and in lymphoid tissues and is highly homologous to the interleukin 8 receptors. EBI 2 is most closely related to the thrombin receptor. EBI 2 is expressed in B-lymphocyte cell lines and in lymphoid tissues but not in T-lymphocyte cell lines or peripheral blood T lymphocytes. EBI 2 is also expressed at lower levels in a promyelocytic and a histiocytic cell line and in pulmonary tissue. These predicted G protein-coupled peptide receptors are more likely to be mediators of EBV effects on B lymphocytes or of normal lymphocyte functions than are genes previously known to be up-regulated by EBV infection.

Epstein-Barr Virus (EBV) is the cause of infectious mononucleosis, a benign proliferation of infected B lymphocytes (36), and can also cause acute and rapidly progressive B-lymphoproliferative disease in severely immunocompromised patients or in experimental infection of tamarins (56). Infection of human B lymphocytes in vitro results in expression of six virus-encoded nuclear proteins (EBNAs) and two virus-encoded membrane proteins (LMPs) (44) and in substantially altered cell growth (61, 62). EBV-infected B lymphocytes recapitulate features of antigen stimulation in enlarging, increasing RNA synthesis, expressing activation antigens and adhesion molecules, differentiating toward immunoglobulin (Ig) secretion, and proliferating (10, 26, 31, 61, 79, 80). Unlike antigen-stimulated B lymphocytes, EBV-infected B lymphocytes continue to proliferate in vitro as immortalized lymphoblastoid cell lines (62).

EBV effects on lymphocytes have been studied by comparing the properties of EBV-negative [EBV(-)] Burkitt's lymphoma (BL) cell lines and EBV-positive [EBV(+)] derivatives, infected by EBV, in vitro (12, 21, 61, 66-68). EBV(-) BL cells resemble proliferating centroblasts of germinal centers, characteristically expressing CD10, CD20, CD77 (BLA), class II antigen, and the carbohydrate recognized by peanut agglutinin (12, 21, 23, 28-30, 66, 67). Both EBV(-) BL cells and centroblasts lack surface IgD and antigens associated with early phases of mitogen stimulation in vitro, including CD23, CD39, and CD30. In general, EBV(+) BL cells closely resemble EBV-infected primary B lymphocytes in not expressing CD10 or CD77 and in expressing early activation and differentiation markers, vimen-

tin, Bac-1, Bcl-2, surface IgD, and CD44 (12, 21, 23, 29, 35, 66, 68, 70, 76, 84-86).

Experiments with single-gene transfer into EBV(-) B-lymphoma cells or with specifically mutated EBV recombinants reveal that EBNA 2, LMP 1, and EBNA 3C are essential for lymphocyte growth transformation and alter cellular or viral gene expression. Expression of EBNA 2 alone in EBV(-) BL cell lines results in enhanced transcription of CD23, CD21 (17, 85, 86), and *c-fgr* (46). EBNA 2 also transactivates the LMP promoters (22, 87). Analysis of a series of EBNA 2 mutants indicates that the ability of EBNA 2 to transactivate gene expression is tightly linked to its essential role in cell growth transformation (16). LMP 1 is also critical to the effects of EBV on cell growth. LMP 1 transforms immortalized rodent fibroblasts (5, 82, 83) and induces vimentin, Bcl-2, and many of the activation markers and adhesion molecules that EBV induces in BL cells or primary B lymphocytes (8, 35, 84, 85). In EBV(-) BL cells, EBNA 3c induces higher-level expression of CD21 (85).

Since altered B-lymphocyte gene expression is a central theme in EBV-induced changes in B-lymphocyte growth, a more complete description of the repertoire of EBV-induced genes would be advantageous before the investigation of specific genes for their role as mediators of EBV effects on cell growth. Genes induced by EBV could also be of importance in B-lymphocyte immunology because of the similar activating and differentiating effects of EBV and antigen. Previously, recognition of such genes has been based largely on increased expression of lymphocyte surface markers (12, 85, 86), defined by monoclonal antibodies derived against EBV- or antigen-activated B lymphocytes. Few of these surface markers are likely candidates for important effectors of EBV- or antigen-induced alterations in

\* Corresponding author.

lymphocyte growth. The experiments described here use subtracted hybridization to identify cDNA clones of RNAs which are more abundant in an in vitro-infected EBV(+) BL cell than in the noninfected EBV(-) control BL cell.

## MATERIALS AND METHODS

**Cells and cell lines.** BL41 and BL30 are EBV(-) BL cell lines. The BL41/B95-8 and BL41/P3HR1 cell lines were derived by infecting BL41 with the transforming EBV strain B95-8 or the nontransforming strain P3HR1, respectively (12, 23). IB4 is a latently infected B lymphoblastoid cell line established by infection of B lymphocytes with EBV (B95-8) in vitro. RHEK-1 (a generous gift from Jong Rhim, National Cancer Institute) is a human keratinocyte line derived by infection of primary foreskin epithelial cells with an adenovirus 12-simian virus 40 hybrid. K562 is a Philadelphia chromosome-positive human chronic myeloid leukemia cell line. U937 is a histiocytic lymphoma cell line with monocytic features. HL60 is a promyelocytic leukemia line. HSB-2 and Jurkat are human T lymphoblastic leukemia cell lines. TK143 was derived from a human osteosarcoma.

Human peripheral blood mononuclear cells (PBMCs) were purified from peripheral blood by centrifugation on a Ficoll cushion (Ficoll-Hypaque; Pharmacia, Vineland, N.J.). Cells were resuspended at  $10^6$  cells per ml in RPMI 1640 medium supplemented with 20% fetal bovine serum and were divided into parallel cultures grown for 72 h with or without 2.5  $\mu$ g of pokeweed mitogen (Sigma, St. Louis, Mo.) per ml. T cells were isolated from purified PBMCs by rosetting overnight with aminoethylisothiuronium bromide (AET)-treated sheep erythrocytes at 4°C followed by centrifugation over Ficoll. Pelleted erythrocytes were lysed with ammonium chloride. The remaining T cells were resuspended at  $10^6$  cells per ml in RPMI 1640 medium with 20% fetal bovine serum. Phytohemagglutinin (Sigma) was added to a final concentration of 1.0  $\mu$ g/ml. Cells were cultured for 72 h and harvested for extraction of total cellular RNA.

**RNA preparation and analysis.** Cytoplasmic RNA was isolated from exponentially growing cells by a modification of the acid phenol-guanidinium isothiocyanate extraction procedure followed by reprecipitation in guanidinium hydrochloride-ethanol. Total cellular RNA was extracted from 0.2- to 2-g samples of human spleen and tonsil obtained from surgical specimens and from human bone marrow obtained postmortem. Tissues were homogenized in acid phenol-guanidinium isothiocyanate by using a rotary tissue homogenizer, extracted, and precipitated. After dissolution in guanidinium hydrochloride and reprecipitation with ethanol, human tissue RNA samples were resuspended in H<sub>2</sub>O and precipitated by addition of an equal volume of 8 M LiCl. The polyadenylated fractions of BL41 or BL41/B95-8 RNA were purified by two successive cycles of chromatography on oligodeoxythymidylate cellulose. Polyadenylated IB4 RNA was purified by a single round of oligodeoxythymidylate selection. RNA samples (12  $\mu$ g per lane) were size fractionated on 0.66 M formaldehyde-1% agarose gels and transferred to charged nylon membranes (GeneScreen Plus; New England Nuclear, Billerica, Mass.) for subsequent hybridization analysis. To examine gene expression in other human tissues, we used a commercially prepared blot containing 2  $\mu$ g each of polyadenylated heart, brain, placenta, lung, liver, kidney, skeletal muscle, and pancreas RNA (Multiple Tissue Northern; Clontech, Palo Alto, Calif.).

Probes were prepared from cloned cDNA inserts by using random hexamer primers and [<sup>32</sup>P]dCTP. The  $\beta$ -actin probe

was generated by using a previously described 1.4-kb cDNA (8). The glyceraldehyde phosphate dehydrogenase probe was prepared from a commercially obtained DNA fragment (Clontech). Filters were hybridized for 18 to 24 h at 47°C in a hybridization buffer consisting of 50% formamide, 6 $\times$  SSPE (20 $\times$  SSPE is 3.0 M NaCl, 200 mM NaPO<sub>4</sub> [pH 7.4] and 20 mM EDTA), 1% sodium dodecyl sulfate (SDS), 1 $\times$  Denhardt's solution (100 $\times$  Denhardt's solution is 2% bovine serum albumin, 2% polyvinylpyrrolidone, and 2% Ficoll), and 100  $\mu$ g of sheared single-stranded herring testis DNA per ml. The filters were washed as specified by the manufacturer, with high stringency washes performed at 67 to 70°C in 1% SDS-0.2 $\times$  SSC (1 $\times$  SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and exposed to preflashed film (X-Omat AR; Kodak, Rochester, N.Y.) at -80°C for 2 h to 10 days. Autoradiographic signal intensities were quantitated by densitometric scanning with a Beckman DU-8 spectrophotometer equipped with a slab gel Compuset module. Induction factors were calculated for each probe as signal intensity ratios for EBV(+) versus EBV(-) cells, divided by the ratio of  $\beta$ -actin signal intensities.

**cDNA library preparation.** First-strand cDNA was prepared from 5  $\mu$ g of polyadenylated BL41/B95-8 RNA by using Moloney murine leukemia virus reverse transcriptase (SuperScript; Bethesda Research Laboratories, Gaithersburg, Md.) and oligodeoxythymidylate primers in a 100- $\mu$ l reaction. Second-strand cDNA was synthesized by using *Escherichia coli* DNA polymerase I and RNase H. The double-stranded cDNA was blunt ended with T4 DNA polymerase and *Eco*RI methylated. After ligation of *Eco*RI linkers, the cDNA was digested with *Eco*RI and size fractionated by gel filtration chromatography on Sepharose CL-4B. The purified cDNA was ligated to phosphorylated lambda gt10 arms (Promega, Madison, Wis.) and packaged (Gigapack Gold; Stratagene, La Jolla, Calif.).

**Subtractive probe preparation.** Radiolabeled cDNA was prepared from 6  $\mu$ g of polyadenylated BL41 or BL41/B95-8 RNA in a 200- $\mu$ l reaction containing 50  $\mu$ g of random DNA hexamers per ml; 0.5 mM each dATP, dGTP, and dTTP; 25  $\mu$ M unlabeled dCTP; 1.0 mCi of [<sup>32</sup>P]dCTP (800 Ci/mmol; New England Nuclear); and 2,000 U of recombinant Moloney murine leukemia virus reverse transcriptase. Reactions were carried out at 42°C for 1 h. After precipitation, reaction products were resuspended in 0.1 M NaOH and incubated for 20 min at 65°C to hydrolyze RNA templates. Probes were neutralized with 0.1 M acetic acid and size fractionated on Sephadex G-50. Biotinylated RNA was prepared from polyadenylated BL41 RNA by using a photoactivatable azido-aryl biotin reagent (Photoprobe Biotin; Vector Laboratories, Burlingame, Calif.) as specified by the manufacturer. Probe fractions were combined with 48  $\mu$ g (for BL41/B95-8 probe) or 12  $\mu$ g (for BL41 probe) of biotinylated BL41 RNA and precipitated with ethanol. BL41/B95-8 probes were hybridized with an eightfold excess (2 mg/ml) of biotinylated BL41 RNA, whereas BL41 control probes were hybridized with a twofold excess (0.5  $\mu$ g/ml) of biotinylated BL41 RNA. Hybridizations and subtractions were performed with the Subtractor kit (Invitrogen, San Diego, Calif.) as specified by the manufacturer instructions. The precipitated cDNA-RNA mixtures were resuspended in 10 to 20  $\mu$ l of H<sub>2</sub>O and heated to 100°C for 1 min. An equal volume of 2 $\times$  hybridization buffer (Invitrogen) was added, and the mixture was incubated at 65°C for 20 to 24 h. Following addition of an equal volume of HEPES buffer (10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES; pH 7.5], 1 mM EDTA), 20  $\mu$ g of streptavidin was added and the mixture

was incubated on ice for 10 min. Biotinylated RNA and RNA-cDNA duplexes, complexed with avidin, were removed by repeated phenol-chloroform extractions. The single-stranded, subtracted BL41 cDNA probe which remained in the aqueous phase was used directly for in situ filter hybridizations. Aqueous-phase BL41/B95-8 cDNA probe was precipitated with ethanol and subjected to a second round of subtraction under identical conditions prior to use in filter hybridizations. Duplicate filters were made from 145-mm plates containing 6,000 recombinant bacteriophage and were hybridized in parallel to equal amounts of BL41/B95-8 or BL41 subtracted probes. The filters were hybridized at 48°C for 48 to 72 h in a buffer consisting of 50% formamide, 6× SSPE, 1% SDS, 10% dextran sulfate, 2× Denhardt's solution, 100 µg of sheared single-stranded herring testis DNA per ml, and 10 µg of poly(rA-rU) (Sigma) per ml. They were then washed at 72°C in 0.2× SSC and exposed to preflashed film (Kodak X-Omat AR) for 3 to 7 days. Differentially expressed genes were identified by overlaying films from corresponding filters. Clones selected on primary screening were rescreened once at low density to verify differential expression and for plaque purification.

**Analysis of clones.** DNA was extracted from bulk liquid cultures of purified lambda gt10 clones and digested with *Eco*RI. cDNA inserts were purified by agarose gel electrophoresis and subcloned into pBluescript(+). Nucleotide sequences were determined and were compared by the BLAST algorithm (3) with known sequences resident in the National Center for Biotechnology Information data bases by using the Experimental GENINFO(R) BLAST Network Service, accessed through the Molecular Biology Computer Research Resource of the Dana-Farber Cancer Institute. Multiple sequence alignments were performed by the method of Higgins and Sharp (37), using the CLUSTAL program (PCGene; IntelliGenetics, Mountain View, Calif.) with open gap and unit gap costs of 10.

**Nucleotide sequence accession numbers.** GenBank accession numbers are L08176 for EBI 1 and L08177 for EBI 2.

## RESULTS

**Identification of cDNA clones of EBV-induced RNAs by subtracted-probe hybridization.** cDNA clones of RNA from an in vitro EBV-infected BL cell line, BL41/B95-8 [EBV(+) BL41], were differentially screened with an EBV(+) BL41 cDNA probe from which sequences complementary to EBV(−) BL41 cell RNA had been specifically removed and with an EBV(−) BL41 control cDNA probe. Sequences complementary to EBV(−) BL41 RNA were removed from the EBV(+) BL41 RNA cDNA probes by two subtractions with an eightfold excess of biotinylated EBV(−) BL41 RNA. Overall, 85 to 95% of the labeled EBV(+) BL41 probe was removed by the two subtractions. EBV(−) BL41 cDNA control probe was subtracted only once; this removed 60 to 85% of the probe, thereby reducing hybridization to plaques containing cDNAs from abundant RNAs so that hybridization to cDNAs from less abundant BL41 RNAs was evident.

Seventy-five phage cDNA clones differentially hybridized to the EBV(+) BL41 probe on the first screen of 75,000 recombinant phage. Twenty-five clones were consistently positive on rescreening. The 18 clones which demonstrated the greatest reactivity with the EBV(+) versus the EBV(−) BL41 cDNA probes were selected for nucleotide sequencing and RNA blot hybridization.

TABLE 1. Summary of EBV-induced RNA-DNA clones

Clone	Gene	cDNA size (kb)	RNA size (kb)	Induction <sup>a</sup>
1.1	CD44	1.3	1.6, 2.2, 5.0	>100×
3.3, 7.3	CD21	2.1, 1.8	4.8	
6.5	MARCKS	2.6	2.9	30×
8.2	Cathepsin H	1.5	1.7	6×
10.4, 11.4	Serglycin	1.1, 1.1	1.4	3.5×
12.3	Annexin VI	2.3	3.0	5×
12.5, 13.0	Vimentin	1.0, 1.8	2.0	
6.4	EBI 1	1.2 (2.14) <sup>b</sup>	2.4	21×
3.2	EBI 2	1.64	1.9	>200×
	β-Actin		2.2	3×

<sup>a</sup> Induction levels were calculated as ratio of signal intensities (BL41/B95-8 to BL41) for individual probes, divided by the ratio of signal intensities for the β-actin probe.

<sup>b</sup> The 1.2-kb EBI 1 clone identified on the initial screen was incomplete. Rescreening of the cDNA library resulted in isolation of several additional full-length clones, the largest of which was 2.14 kb.

<sup>c</sup> Induction of β-actin RNA was calculated as the ratio of actin signal intensities (BL41/B95-8 to BL41) divided by the ratio of signal intensities for glyceraldehyde phosphate dehydrogenase probe.

**Nucleotide sequences of EBV-induced cDNAs.** The first 12 clones are described in Table 1. Ten clones matched seven previously characterized genes: two independent clones each of the genes for complement receptor type 2 (CD21), the serglycin proteoglycan core protein, and vimentin; and one clone each of the genes for cathepsin H, annexin VI (p68), the myristylated alanine-rich protein kinase C substrate (MARCKS), and the lymphocyte hyaluronic acid receptor (CD44). The 2.6-kb MARCKS cDNA precisely matched the previous 1.58-kb human MARCKS cDNA clone (32) at its 5' end (7a). The 3' untranslated region of the new clone is highly homologous to bovine MARCKS cDNA (75).

The two remaining clones are from novel RNAs, EBV-induced genes 1 (EBI 1) and 2 (EBI 2), whose nucleotide sequences can be predicted to encode G protein-coupled peptide receptors. The complete nucleotide and deduced amino acid sequences of the EBI 1 and EBI 2 cDNAs are shown in Fig. 1A B, respectively. Because the first EBI 1 cDNA was 1.2 kb, significantly shorter than the 2.4-kb RNA, 20 other cDNA clones were obtained by using the initial cDNA as a probe. The largest clone is 2,153 nucleotides (nt) and has a 1,134-nt open reading frame (Fig. 1A). This clone is probably nearly full length, since it is close to the expected size, considering that it has only a short poly(A) tail. Translation is likely to initiate from either of two AUGs, at nt 64 to 66 or nt 82 to 84, the first of which conforms to a consensus translational initiation sequence (49). An in-frame stop codon at nt 10 to 12 is consistent with translational initiation at nt 64 to 66. The polypeptide encoded by the sequence beginning at nt 64 has a predicted molecular mass of 42.7 kDa and includes eight hydrophobic domains likely to mediate membrane insertion. The first hydrophobic domain begins at the amino terminus and ends at a predicted signal peptidase cleavage site. The seven remaining hydrophobic domains are characteristic of the G protein-coupled receptor family. A potential asparagine-linked glycosylation site is encoded as part of the extracellular amino-terminal segment and as part of the third extracellular loop.

Since the initial EBI 2 cDNA was 1,643 nt and approximated the size expected from a 1.9-kb polyadenylated RNA, further cDNA clones were not obtained. The EBI 2 cDNA contains a 1,083-nt open reading frame with two methionine

A

GGAATTCGGTAGTGGAGGGGGGACAGCCTTCTGTGTGTTTACGGCCAGAGAGCGTCATGGAGCTGGGAAACCAATGAAAAGC 90  
 \*\*\* METAspLeuGlyLysProMetLysSer 9

GTGCTGGTGGTGGCTCTCTTGTCAITTTTCAGGTATGCGCTGTGCAAGATGAGGTACGGACGATTACATCGGAGACAACACCACAGTG 180  
 ValLeuValValAlaLeuLeuValIlePheGlnValCysLeuCysGlnAspGluValThrAspAspTyrIleGlyAspAsnThrThrVal 39  
 CHO#####

GACTACACTTTGTTCCAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACCTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTGT 270  
 AspTyrThrLeuPheGluSerLeuCysSerLysLysAspValArgAsnPheLysAlaTrpPheLeuProIleMetTyrSerIleIleCys 69

TTCGTGGGCTACTGGGCAATGGGCTGGTGGTGTGACCTATATCTATTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAAC 360  
 PheValGlyLeuLeuGlyAsnGlyLeuValValLeuThrTyrIleTyrPheLysArgLeuLysThrMetThrAspThrTyrLeuLeuAsn 99

CTGGCGGTGGCAGACATCCTCTCTCTGACCTTCCCTTCTGGGCTACAGCGGGGCAAGTCTGGGTCTTCGGTGTCCACTTTTGC 450  
 LeuAlaValAlaAsnIleLeuPheLeuLeuThrLeuProPheTrpAlaTyrSerAlaAlaLysSerTrpValPheGlyValHisPheCys 129

AAGCTCAITCTTTGCCATCTACAAGATGAGCTTCTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTC 540  
 LysLeuIlePheAlaIleTyrLysMetSerPhePheSerGlyMetLeuLeuLeuLeuCysIleSerIleAspArgTyrValAlaIleVal 159  
 ::::::::::::::::::::::::::::::

CAGGCTGTCTCAGCTACCGCCACCGTGGCGGCTCTTCTCATCAGCAAGCTGTCTGTGTGGCAGCGCCATACTAGCCACAGTGCTC 630  
 GlnAlaValSerAlaHisArgHisArgAlaArgValLeuLeuIleSerLysLeuSerCysValGlySerAlaIleLeuAlaThrValLeu 189

TCCATCCAGAGCTCCTGTACAGTACCTCCAGAGGAGCAGCAGTACGAGCAAGCGATGCGATGCTCTCATCACAGAGCATGTGGAGGCC 720  
 SerIleProGluLeuLeuTyrSerAspLeuGlnArgSerSerSerGluGlnAlaMetArgCysSerLeuIleThrGluHisValGluAla 219

TTTATCACCATCCAGGTGGCCAGATGGTGCATCGGCTTCTGGTCCGCTGCTGGCCATGAGCTTCTGTTACCTTGTGATCATCCGCACC 810  
 PheIleThrIleGlnValAlaGlnMetValIleGlyPheLeuValProLeuLeuAlaMetSerPheCysTyrLeuValIleIleArgThr 249

CTGTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTGTGCTTTCATAGTCTTCCAGCTGCCCTAC 900  
 LeuLeuGlnAlaArgAsnPheGluArgAsnLysAlaIleLysValIleIleAlaValValValValPheIleValPheGlnLeuProTyr 279

AATGGGCTGGTCTGGCCAGCAGCTGGCCAACTTCAACATCACCAGTAGCAGCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGAC 990  
 AsnGlyValValLeuAlaGlnThrValAlaAsnPheAsnIleThrSerSerThrCysGluLeuSerLysGlnLeuAsnIleAlaTyrAsp 309  
 CHO#####

GTCACCTACAGCCTGGCTGGCTGGCTGGCTGCTGCTCAAGCCTTCTTGTACGCTTCATCGGCGTCAAGTTCCGCAACGATATCTTCAAG 1080  
 ValThrTyrSerLeuAlaCysValArgCysCysValAsnProPheLeuTyrAlaPheIleGlyValLysPheArgAsnAspIlePheLys 339

CTCTTCAAGGACCTGGGCTGGCTCAGCCAGGAGCAGCTCCGCGAGTGGTCTTCTCTCGGCACATCGGCGCTCCTCCATGAGTGTGGAG 1170  
 LeuPheLysAspLeuGlyCysLeuSerGlnGluGlnLeuArgGlnTrpSerSerCysArgHisIleArgArgSerSerMetSerValGlu 369

GCGGAGACCACCAACCTTCTCCCCATAGGCGACTCTTCTGCTGGACTAGAGGACCTCTCCAGGGTCCCTGGGCTGGGGATAGGGA 1260  
 AlaGluThrThrThrThrPheSerPro\*\*\* 375

GCAGATGCAATGACTCAGGACATCCCCCGCCAAAAGCTGCTCAGGGGAAAAAGCAGCTCTCCCTCAGAGTGCAGGCGCTGCTCCAGA 1350  
 AGATAGCTTACCCCAATCCAGCTACCTCAACCAATGCCAAAAAAGACAGGGCTGATAAGCTAACACAGACAGACAACACCTGGGAAA 1440  
 CAGAGCTATTGCGCCCTAAACCAAACTCAAACTCAAACTCCACAACTCTCCAGCTCCTCCAGTCAACCGCCCAACACCTGAC 1530  
 TGCAGGGGGCGTGGGCTGAAGACTCTCTGAATGAACCTTCTGGCTCCGACAGACTCAATGCTCAGCAGCTCTTCCGAAA 1620  
 ACCAGGCTTATCTCAAGACAGAGATAGTGGGAGACTTCTGGCTTGGTGGAGAAAAAGGCACATCAGCTGGTCAAAACAACTCTCT 1710  
 GAACCCCTCCCTCCATCCTTTCTTCACTCTCTCAAGCCAGCGGGAATGGCAGTGGCCAGCGCCCTAAAGACACACTCATCCCTC 1800  
 ACTTGGCGCTGCGCTCCAGGCTCTCAACAGGGGAGAGTGTGGTGTTCCTGAGGGCAGGCGAGCTGCTCCGCTGATCAAGGCA 1890  
 CACTCTGGGCTCAGAGTGGGATGACATGCACTCAGCTTGGCTCCACTGGGATGGGAGGAGACAAAGGAAATGTGAGGGGGGG 1980  
 GAGGGTGACAGTGGCGGCCAAGGCCAGCTTGTCTTTGTTTGTACAGGGACTCAAAACCTCTCCTCATGTTCTGCTTTCGAT 2070  
 TCGTTAAGAGAGCAACATTTTACCCACACAGATAAAGTTTCCCTTGGAGAAACACAGCTTTAAAAAAGCAATTTC 2154

FIG. 1. Nucleotide and deduced amino acid sequences of EBI 1 and EBI 2 RNAs. (A) EBI 1 has two potential translational initiation codons. In-frame stop codons are indicated by asterisks. A hydrophobic amino-terminal segment (single underline) is predicted to be a signal peptide for membrane translocation. Seven other highly hydrophobic segments are predicted to form membrane-spanning domains and are delineated by double underlines. Potential asparagine-linked glycosylation sites (CHO#####) are present in the extracellular amino-terminal segment and third extracellular loop. The sequence motif S-(I/V)-D-R-(Y/F)-X-X-X-X (where X represents consecutive hydrophobic residues) is highly conserved among a large number of G protein-coupled receptors and is indicated at the end of the third transmembrane domain (::::). (B) EBI 2 has two possible initiator methionine codons. Predicted transmembrane domains are indicated (double underlines). No signal sequence was identified.

codons at nt 34 to 36 and 46 to 48 (Fig. 1B). Although neither methionine codon is in a favored initiation context (49), the presence of an upstream in-frame termination codon and the absence of other potential open reading frames are consistent with translation initiation at the first or second methionine codon. Initiation at the first would result in a 41.2-kDa

protein. The deduced amino acid sequence predicts seven hydrophobic transmembrane segments in the characteristic configuration of a G protein-coupled receptor. In contrast to the EBI 1 protein, EBI 2 lacks a signal peptide. The amino-terminal putative extracellular domain has a potential N-linked glycosylation site. Although the EBI 2 cDNA lacks

## B

GGAATTCCTCGATATACACCTGGACCACCACCAATGCATATACAAATGGCAACAATTTTACTCGCCCTCTGCAACTCCTCAGGAAAT	90
*** METAspIleGlnMETAlaAsnAsnPheThrProProSerAlaThrProGlnGlyAsn	19
CHO#####	
GACTGTGACCTCTATGCACATCAGCAGCGCCAGGACTAATGCCTCTGCATTACAGCCTCGTCTTCATCATTGGGCTCGTGGAAAC	180
AspCysAspLeuTyrAlaHisHisSerThrAlaArgIleValMetProLeuHisTyrSerLeuValPheIleIleGlyLeuValGlyAsn	49
TTACTAGCCTTGGTCTGCTATTGTTCAAAACAGCAAAAAATCAACTCTACCACCTCTATTCAACAAATTTGGTGATTCTGATATACTT	270
LeuLeuAlaLeuValValIleValGlnAsnArgLysLysIleAsnSerThrThrLeuTyrSerThrAsnLeuValIleSerAspIleLeu	79
TTTACCACCGCTTTGGCTACAGCAATAGCCTACTATGCAATGGCCTTTGACTGGAGAATCGGAGATGCCTTGTGTAGCATACTGGCCTA	360
PheThrThrAlaLeuProThrArgIleAlaTyrTyrAlaMetGlyPheAspTrpArgIleGlyAspAlaLeuCysArgIleThrAlaLeu	109
GTGTTTTACATCAACAGATATGCAGGTGTGAACCTTTTACCTGCCTGACTATTGACCGCTTCATTGCTGTGCTGCACCTCTACGCTAC	450
ValPheTyrIleAsnThrTyrAlaGlyValAsnPheMetThrCysLeuSerIleAspArgPheIleAlaValValHisProLeuArgTyr	139
.....	
AACAAGATAAAAGGATTGAACATGCAAAAGCGCTGTGCATTTTCTGCTAGTATTGCTGAGACACTCCCACTCCTCATCAAC	540
AsnLysIleLysArgIleGluHisAlaLysGlyValCysIlePheValTyrIleLeuValPheAlaGlnThrLeuProLeuLeuIleAsn	169
CCTATGTCAAAGCAGGAGGCTGAAAGGATTACATGCATGGAGTATCCAACTTTGAAGAACTAAATCTCTCCCTGGATTGCTTGGG	630
ProMetSerLysGlnGluAlaGluArgIleThrCysMetGluTyrProAsnPheGluGluThrLysSerLeuProTyrIleLeuLeuGly	199
GCATGTTTCATAGGATATGTAAGTCTTCCACTTATAATCATTCTCATCTGCTATTCTCAGATCTGCTGCAAACTCTTCAGAACTGCCAAACAA	720
AlaCysPheIleGlyTyrValLeuProLeuIleIleIleLeuIleCysTyrSerGlnIleCysCysLysLeuPheArgThrAlaLysGln	229
AACCCACTCACTGAGAAATCTGGTGTAAACAAAAGGCTCTCAACACAATTATTCTTATTATTGTTGTGTTTCTCTGTTTACACCT	810
AsnProLeuThrGluLysSerGlyValAsnLysLysAlaLeuAsnThrIleIleLeuIleIleValValPheValLeuCysPheThrPro	259
TACCATGTTGCAATTATTCAACATATGATTAAGAAGCTTCGTTTCTCTAATTTCTGGAATGAGCCAAAGACATTGCTCCAGATTCT	900
TyrHisValAlaIleIleGlnHisMetIleLysLysLeuArgPheSerAsnPheLeuGluCysSerGlnArgHisSerPheGlnIleSer	289
CTGCACCTTACAGTATGCTGATGAAGTTCATTCCTGCATGGACCTTTTATCTACTTCTTTGCATGTAAAGGTTAAGAGAAAGGTT	990
LeuHisPheThrValCysLeuMetAsnPheAsnCysCysMetAspProPheIleTyrPhePheAlaCysLysGlyTyrLysArgLysVal	319
ATGAGGATGCTGAAACGGCAAGTCAGTGTATCGATTCTAGTGTGTGAAGTCAGCCCTGAAGAAATTCAGGTGAAATGACAGAAACG	1080
MetArgMetLeuLysArgGlnValSerValSerIleSerSerAlaValLysSerAlaProGluGluAsnSerArgGluMetThrGluThr	349
CAGATGATGATACATTCCAAGTCTTCAAATGGAAGTGAATGCATTGTAITTTGGTTTATAGTGACGTAAACTGTATGACAACTTTGC	1170
GlnMetMetIleHisSerLysSerSerAsnGlyLys***	361
AGCACTTCCTTATAAGCAAAATAATTGTTCACTTCCAATTACTATTCTTTTATATTCTTTTCAATGGGCGCTTTCCCATCTCCAAC	1260
CGGAAGTAAGCCCAAGAGAACACATAAAGCAACACATAAAGCACAATAAATGCAATAAATATTTCATTTTATTGTAACGA	1350
ATACACCAAAAGGAGCGCTCTTAATAACTCCCAATGTAAAAAGTTTGTTTTAAATAAAAAATTAATTATTCTTCCCAACAAATGGC	1440
TAGAAAGCACTGAATAGATTATATATGCCAGATGTTAATACTGTAACATACTTTTAAATAACATATTCTTAAATCCAAATTTCTCTC	1530
AATGTTAGATTAAATTCCTCAATAACCAATGTTTGTGTTTCTGCTCTGCTCATAAACTTTGTTAAGGAAGCTTTTGGGAATA	1620
AAGAGCAGGATGCTGCGGAATTC	1644

FIG. 1—Continued.

a polyadenylate tail, a canonical polyadenylation signal (AATAAA) near the 3' end is consistent with the conclusion that the cDNA is essentially complete.

Comparison of EBI 1 and 2 with other G protein-coupled receptors. The EBI 1 and EBI 2 nucleotide and predicted amino acid sequences were compared with the GenBank (release 72 and updates), EMBL (release 31), GenBank translation, Swiss protein (release 22) and Protein Identification Resource (PIR; release 33) data bases by using the BLAST algorithm (3). EBI 1 and EBI 2 are homologous to G protein-associated receptors. EBI 1 is highly homologous to the human high- or low-affinity interleukin 8 (IL-8) receptors at both the nucleotide (data not shown) and amino acid (Fig. 2A) sequence levels. These IL-8 receptors are not expressed on lymphocytes (38, 59). Excluding the putative EBI 1 signal peptide, the overall amino acid identity among the three proteins exceeds 30%, with conservative changes observed at many of the nonidentical residues. The identity increases

to 40% when EBI 1 is compared with either IL-8 receptor individually. Additional similarities with the IL-8 receptors include a high proportion of serine and threonine near the carboxy terminus and a highly acidic amino-terminal extracellular domain. The IL-8 receptor acidic residues are implicated in binding IL-8 basic amino acids (38, 59).

The EBI 2 gene does not have such a close homolog. EBI 2 has 24% amino acid identity with the thrombin receptor (Fig. 2B; data not shown) (81). Less extensive homologies are observed with a number of other G protein-coupled receptors, including the receptors for vasoactive intestinal polypeptide, somatostatin (type 1), and angiotensin II, as well as with the low-affinity IL-8 receptor (Fig. 2B). EBI 2 also exhibits more distant homologies with EBI 1 and the high-affinity IL-8 receptor. Significantly, these are the same proteins which, in a different order, exhibit the closest homologies with the EBI 1 protein. Together they constitute a subfamily of G protein-coupled peptide receptors. The

A		
EBI 1	MDLGKPMKSVLVVALLVIFQVCLQDEVTDYDIGNNTTVDTLFEISLCSKDKVRN	55
IL-8 RL	ME-----SDSFEDFW-----KGEDLSNYSSTLPFFLLDAAPC-EPESE	40
IL-8 RH	MS-----NITDPQMW-----DFDDLN---PTG-MPPADEDYSFC-MLETET	36
	*. . . . .	
TM I TM II		
EBI 1	PKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDYLLNLAVADILPLLT	110
IL-8 RL	INKYFVVIIYALVFLSLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALT	95
IL-8 RH	LNKYVVIIYALVFLSLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALT	91
	*****. . . . .	
TM III		
EBI 1	LPPWAYSAAKSWVFGVHFKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAH	165
IL-8 RL	LPIWAASKVNGWIFGTFLCKVSVLLKEVNFYSGILLACISVDRYLAIVHATRTL	150
IL-8 RH	LPIWAASKVNGWIFGTFLCKVSVLLKEVNFYSGILLACISVDRYLAIVHATRTL	146
	*****. . . . .	
TM IV		
EBI 1	RHRARVLLISKLSGVSAIATVLSIPELLYSDLRSSSEQAMRCSLITEHVEAF	220
IL-8 RL	TQK-RYLV--KFICLSINGLSLLALPVLFRRTVYSSNVSPACYEDMGNTANW	202
IL-8 RH	TQK-RHLV--KFCVLCGWSLHNSLPPFFLRQAYHPNNSPVCYEVLGNOTAKW	198
	..*.*.*.*.*. . . . .	
TM V TM VI		
EBI 1	-ITIQVQMVIGFVPLLLAMSPCYLVIIIRTLQARNFERNKAIVVAVVVFIV	274
IL-8 RL	RMLLRILPQSFGFIVPLLMFLCYGFTLRITLFAHMGQKRAMRVIFAVVLIPLL	257
IL-8 RH	RMVLRILPHTFGFIVPLFVLMFLCYGFTLRITLFAHMGQKRAMRVIFAVVLIPLL	253
	..*.*.*.*.*. . . . .	
TM VII		
EBI 1	FQLPYNGVLAQTVANFNITSSSTCELSKQINIAVDVTYSLACVRCVNPFLYAFI	329
IL-8 RL	CWLPYNLVLLADTLMTQVIQETCERRNHIDRALDATEILGLHSCINPLIYAFI	312
IL-8 RH	CWLPYNLVLLADTLMTQVIQETCERRNHIDRALDATEILGLHSCINPLIYAFI	308
	*****. . . . .	
EBI 1	GVKFRNDIFKLFKDLGCLSQEQLRWSSCRHRRSSMSVEAETTTTFSP	379
IL-8 RL	GQKFRHGLLKILAIGHGLSKDSLFPK-----DSRPSFVGSSSGHTSTTL	355
IL-8 RH	GQKFRHGLLKILAMHGLSVSKEFLAR-----HRVTSYT-SSSVNVSSNL	350
	*. . . . .	
B		
TM I TM II		
EBI 1	IICFVGLLGNGLVVLTYIYFKRLKTMTDYLLNLAVADILPLLTLPFWAYSAAKS	121
IL-8 RL	LVFLSLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLPALTLPWAASKVNG	106
IL-8 RH	LVFLSLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLPALTLPWAASKVNG	102
NY2 R (Bov)	IIFITGIVGNGLVILVHGQKQLRSMTDQYRLHLSVADLLFVLTLFPWAVDVA	102
EBI 2	LVFIIGLVGNLLALVUVQNRKKINSTLYSTNLVISDILFTALPRTIAYYANG	94
Thrombin R	GVFVVSFLPNTMAIVVFILKMKVKKPAVVYMLHLATADVLFVSVPFKISYPSG	165
VIP R	PIFVIGMIANSVVVWNIQAKTTGYDTHCYILNLAIDLWVLTIPVWVSLVQH	107
ANGT II R	IIFVVGIFGNSLVVIVYFYMMLKTVASVFLNLALADLCFLTLPLWAVYTAME	91
SOM R 1	VVCVLGCGNSMVIVVILRYAKKKTATNIYILNLAIDELLMLSVFPLVTSTLLR	121
	*****. . . . .	
ECRF3	LMFLCNAIGNSLVLRITFLKYR AQAQSFYIMMGFCNLISLFLAGYLLMRLRM	106
HCMVUS27	LMCIQVTFENLVITTLTYRRKSPSDTYICNLAVADLLIVGLPFFLEYAKH	112
HCMVUS28	VVFLFGSIGNFLVITFTWRRRIQCSGDVYFINLAADLLFVCTLPWMQYLL	111
HCMVUS33	FILFVGGLNAIVLITOLLNRVYSTPTIYMTNLYSTNFLTTLVLPFIVLSNQ	112
TM III		
EBI 1	--WVFGVHFKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLI	174
IL-8 RL	--WIFGTFLCKVSVLLKEVNFYSGILLACISVDRYLAIVHATRTLQK-RYLV-	157
IL-8 RH	--WIFGTFLCKVSVLLKEVNFYSGILLACISVDRYLAIVHATRTLQK-RHLV-	153
NY2 R (Bov)	--WYFGKFLCKAVHVIYTVNLYSSVLLAFISLDRYLAIVHATN--SQKPKLLA	153
EBI 2	FDWRIGDALCRITLVFYINTYAGVNFMTCLSIDRFIAVHPLRYNK--IKRIEH	147
Thrombin R	SDWQFGSELCRFVTAAFCNMYASILLMTVISIDRFVAVVPMQSL--WRTLGR	218
VIP R	NQWPMGELTCKVTHLIFSINLFSGIFPLTMSVDRYLSITYFTN--TPSSRKQMV	160
ANGT II R	YRWPFGNVLCIASASVSPNLYASVFLITCLSIDRYLAIVHFMK--SRLRRTLV	144
SOM R 1	-HWPFGALLCRLVLSVDAVNMTFTIYCLTVLSVDRYVAVVHPYKA--ARYRRTV	173
	*. . . . .	
ECRF3	FEIPMNTLCKLEAFFLNLSIYWSPPILVFISVLRCLIFCATR LWVKTTLIGQ	170
HCMVUS27	HPKLSREVCSGLNACFYICLFGVCFILNLSMDRYCVIWGVELNRVRNKRAT	169
HCMVUS28	DHNSLASVPCITLLTACFYVAMFASLCFITEIALDRYVAIV MRYRPVKQAC	169
HCMVUS33	WLLPAGVASCKFLSVIYSSCTVGATVALIAADRYRVLHK RTYARQSYRSTY	169

FIG. 2. Protein sequence homologies between EBI 1 and EBI 2 and previously identified G protein-coupled receptors (74). Positions of predicted transmembrane domains I through VII (TM I through TM VII) are indicated by horizontal lines above the corresponding sequences. Amino acids identical in all aligned sequences are indicated by an asterisk. Conservative changes are indicated by a dot. (A) Alignment of EBI 1 with high-affinity (IL-8 RH) and low-affinity (IL-8 RL) IL-8 receptors. (B) Alignment of EBI 2 with EBI 1 and receptors for thrombin (81), IL-8 (IL-8 RL, IL-8 HL), vasoactive intestinal polypeptide (VIP R) (71), angiotensin II (ANGT II R) (19), bovine neurotrophin Y [NY2 R (Bov)] (64), and somatostatin receptor type 1 (SOM R 1) (89). A proposed alignment with the G protein-coupled receptor homologs of herpesvirus saimiri (ECRF3) (60) and of human cytomegalovirus (HCMVUS27, HCMVUS28, and HCMVUS33) (14) is shown below.




FIG. 3. RNA blot hybridization analysis of EBV-induced cellular gene expression. Polyadenylated RNA (4 to 12  $\mu$ g per lane) was size fractionated on formaldehyde-agarose gels, transferred to charged nylon membranes, and hybridized with the probes indicated at the bottom of each autoradiograph panel. RNA samples used are indicated at the top of each lane (lane LCL, EBV-immortalized primary B lymphoblastoid cell line, [IB4]; lane BL, EBV-negative BL cell line [BL41]; EBL, EBV-infected BL cell line [BL41/B95-8] derived by *in vitro* infection of BL41). Dashes indicate positions of rRNA bands (18S, 28S). The band detected at 1.5 kb in lane LCL by the P68 probe is due to residual signal from a prior hybridization.

greatest conservation of residues among these proteins extends from the first transmembrane domain (Fig. 2B; TM I) to the second intracellular loop. Because of the particular conservation of an amino acid sequence among these G protein-coupled receptors, we were able to identify a new highly conserved sequence motif at the carboxy end of TM III and the adjacent second intracellular loop. This motif, S-(I/L)-D-R-(Y/F)-X-X-X-X, with X being a hydrophobic amino acid, is present in a wide variety of G protein-coupled receptors but is not present in other proteins in the data bases surveyed. Other highly conserved features of G protein-coupled receptors in EBI 1 and EBI 2 include the asparagine in TM I, the proline in TM II, the aspartate in the first intracellular loop, and the tryptophan and cysteine in the first extracellular loop. This cysteine has been postulated to be involved in disulfide linkage to a conserved cysteine present in the second extracellular loop in several other receptors, including the  $\beta$ -adrenergic and thrombin receptors.

**Analysis of induced gene expression by RNA blot hybridization.** Probes from seven of the nine EBV-induced cDNAs (vimentin and CD21 were previously shown to be EBV induced and were not further evaluated) were hybridized to identical blots of polyadenylated RNA from the EBV(+) or EBV(-) BL41 cell lines or from the EBV-transformed lymphoblastoid cell line IB4 (Fig. 3). The RNAs loaded in the EBV(+) BL41 and EBV(-) BL41 lanes were standardized with respect to  $\beta$ -actin reactivity. Significantly less IB4 cell RNA was used because of the high abundance of the putative induced-gene RNAs in these cells (Fig. 3, actin probe). Probes from each of the cDNA clones detected RNAs which are significantly more abundant in both IB4 and EBV(+) BL41 cells than in EBV(-) BL41 cells. Induction factors indicated in Table 1 were determined by quantitative densitometric scanning of autoradiographs and reflect the fold enhancement of signal intensities in EBV(+) BL41 cells over those in EBV(-) BL41 cells, corrected for the ratio of actin reactivities. Standardization by actin reactivity, however, significantly underestimates the absolute induction levels since actin is induced threefold by EBV infection of BL41 cells relative to glyceraldehyde phosphate dehydrogenase (data not shown) or total RNA amounts quantitated spectrophotometrically. So that the actin signal intensities would be equal, threefold more EBV(-) BL41 than EBV(+) BL41 RNA was loaded per lane. Importantly, each of the RNAs was at least as abundant relative to glyceraldehyde phosphate dehydrogenase in IB4 cells as in EBV(+) BL41 cells (Fig. 3; data not shown).

The EBI 1, EBI 2, CD44, and MARCKS genes are the most highly induced of the seven genes, being induced 21, >200, >100, and 30 times background, respectively, relative to actin (Table 1). The CD44 gene encodes three distinct RNAs of 1.6, 2.2, and 4.8 kb in both IB4 and EBV(+) BL41 cells. No CD44 RNA was detected in EBV(-) BL41 cells even after prolonged autoradiographic exposures. EBI 2 RNA was also undetectable in EBV(-) BL41 cells.

**Expression of EBI 1 and EBI 2 in human cell lines and tissues.** The expression of EBI 1 and EBI 2 in human cell lines and tissues was evaluated by hybridizing actin, EBI 1, or EBI 2 probes to blots of cell line or tissue RNAs. Although EBI 1 is weakly expressed in BL41, EBI 2 is not; also, neither EBI 1 nor EBI 2 is expressed in another EBV(-) BL cell line, BL30 (Fig. 4). EBI 1 and EBI 2 RNAs are abundant in primary human lymphocytes transformed by EBV *in vitro* and propagated as continuous lymphoblastoid cell lines for several years (IB4) or for less than 1 year (LCL-W91) (Fig. 4). EBI 1 RNA is faintly detectable in the human T-cell line Jurkat and is abundantly expressed in a second T-cell line, HSB-2 (Fig. 4). EBI 2 RNA is not detected in either of these T-cell lines (Fig. 4) or in a third T-cell line, Molt-4 (data not shown). EBI 1 is not expressed in the human promyelocytic line HL60, the chronic myelogenous leukemia cell line K562, the epithelial cell line RHEK-1, the fibroblast-like osteosarcoma cell line TK143, or the monocytic cell line U937 (Fig. 4). EBI 2, however, is expressed weakly, relative to actin, in HL60, U937 (U937 RNA is partially degraded), and HeLa (Fig. 4; data not shown) cells.

EBI 1 and EBI 2 RNAs are abundant in human spleen tissue, somewhat less abundant relative to actin in tonsil tissue, and undetectable in bone marrow (Fig. 4). Both genes were expressed in resting PBMCs at levels comparable to those in IB4 or LCL-W91 B lymphoblastoid cells (Fig. 4). Expression increased in parallel cultures stimulated for 72 h with pokeweed mitogen, although actin expression also increased after pokeweed mitogen treatment (Fig. 4). The EBI 1 and EBI 2 RNA in stimulated and nonstimulated PBMC cultures is likely to be mostly in B lymphocytes since EBI 1 RNA is present at low levels and EBI 2 RNA is absent in phytohemagglutinin-stimulated, PBMC-derived T lymphocytes (Fig. 4). These findings are consistent with the expression patterns observed in T-cell lines.

EBI 1 and EBI 2 RNA levels in a variety of nonhematopoietic human tissues were also evaluated. The EBI 1 probe detects small amounts of RNA in both lung and pancreas tissues (Fig. 5). Rehybridization of this blot with an Ig mu




FIG. 4. Expression of EBI 1 and EBI 2 receptor genes in human lymphoid tissues and cell lines.  $^{32}$ P-labeled probes indicated at the left of each panel were hybridized to blots containing RNA from the cell lines indicated at the top of each lane. BL41 and BL30 are EBV-negative BL cell lines; BL41/P3HR1 is infected with a non-transforming EBV strain, P3HR1; BL41/B95-8 is infected with a transforming EBV strain; IB4 is a cell line derived by infecting primary B lymphocytes with EBV of the B95-8 strain; LCL-W91 is a recently established cell line transformed with EBV W91; TONSIL is unfractionated cells from surgically excised human tonsils; PBMC is unfractionated peripheral blood mononuclear cells; PBMC PWM is PBMC stimulated for 72 h with pokeweed mitogen (2.5  $\mu$ g/ml); PBT PHA is T cells purified from PBMC by sheep erythrocyte rosetting, stimulated for 72 h with phytohemagglutinin (1  $\mu$ g/ml); B MARR is postmortem bone marrow; SPLEEN is unfractionated cells from surgically excised spleen; HL60 is a promyelocytic leukemia cell line; U937 is a monocytic leukemia cell line; K562 is a chronic myelogenous leukemia cell line; JURKAT is a T-cell leukemia cell line; HSB-2 is a T-cell acute lymphoblastic leukemia cell line; RHEK-1 is an adenovirus-simian virus 40-transformed human keratinocyte; TK143 is an osteosarcoma cell line. Each panel is a composite prepared from autoradiographs of two separate blots for each probe.

chain probe (Fig. 5, Ig  $\mu$  probe) indicated that these tissue preparations contained significant amounts of Ig RNA, probably because of the presence of B lymphocytes in the tissues. Since EBI 1 RNA is abundant in peripheral blood lymphocytes, the EBI 1 RNA in the lung and pancreas tissues is likely to be due to B lymphocytes. Similarly, the low level of EBI 2 RNA detected in pancreas tissue is probably due to infiltrating B lymphocytes (Fig. 5). However, the abundance of EBI 2 RNA in lung tissue is too great to attribute to lymphocyte contamination and is more likely to be due to specific expression in pulmonary epithelial cells or macrophages (Fig. 5).

## DISCUSSION

The present studies were undertaken to elucidate the mechanisms of EBV transformation of B lymphocytes by identifying cell genes whose expression is increased by EBV infection. By identifying genes induced in EBV(+) versus EBV(-) BL cells, the effects of EBV infection were observed in human B lymphocytes, the natural target of EBV infection and growth transformation. Differences in gene expression that were not due to EBV infection were mini-




FIG. 5. EBI 1 and EBI 2 gene expression in human tissues. EBI 1, EBI 2, and Ig  $\mu$  chain (Ig  $\mu$ ) probes were hybridized to RNA samples from the following human tissues: heart (HE), brain (BR), placenta (PL), lung (LU), liver (LI), skeletal muscle (SM), kidney (KI), and pancreas (PA). Numbers at the left indicate positions and sizes (in kilobases) of RNA markers. Specific RNA bands are indicated by arrows to the right of each panel. The EBI 1 probe detects faint 2.4-kb bands in lung and pancreas RNA. The EBI 2 probe detects an abundant 1.9-kb band in lung RNA and a faint 1.9-kb band in pancreas RNA. The 2.7-kb Ig  $\mu$  RNA is detected in lung, liver, and pancreas preparations. The 1.5-kb band in placental RNA hybridized with Ig  $\mu$  probe is residual signal from a previous hybridization.

mized as a result of the isogenic background of these cells. Further, since the full repertoire of EBV genes expressed in growth-transformed B lymphocytes is expressed in the infected BL41 cells, many effects of these genes on cell gene expression are evident. Consequently, a large number of EBV-induced genes are being identified for the first time, including some novel genes likely to be mediators of B-lymphocyte growth or differentiation.

This report describes the identification of nine EBV-induced genes, CD21 and vimentin genes being the only two which were previously known to be EBV induced (8, 12). CD21 is the EBV receptor, and CD21 mRNA is induced within 36 h following in vitro infection or antigen stimulation of normal peripheral blood B cells (2, 72). EBV induction of CD21 may be a consequence of activating and differentiating effects. Gene transfer experiments in EBV(-) BL cells indicate that CD21 expression is increased by EBNA 2 or EBNA 3C expression (17, 85, 86). CD21 is also the receptor (CR2) for the C3d fragment of complement (88), associates with Ig in the B lymphocyte plasma membrane (77), and may mediate the stimulating effects of antigen-antibody and complement complexes on uninfected B lymphocytes (53).

Vimentin expression is likely to be a consequence of EBV activating effects. Vimentin is the predominant intermediate filament protein in lymphocytes and is expressed at high levels in EBV-transformed B lymphocytes (8). It associates with LMP 1 at the cell periphery (50). Infection of BL41 or BL30 cells in vitro increases vimentin mRNA and protein production (8). In gene transfer studies, LMP 1 alone can induce vimentin expression in EBV(-) Louckes or BL41 BL cells (8).

Similarly, induction of MARCKS, serglycin, cathepsin H, annexin VI, and CD44 is likely to be a consequence of EBV-activating or -differentiating effects on B-lymphocyte structures. Ig cross-linking in normal murine peripheral blood B cells results in specific phosphorylation and dramatically increases the synthesis of MARCKS protein (39, 40). Steady-state MARCKS RNA levels may be regulated in part by mRNA stability (11). The unusually high degree of homology among three prime untranslated regions of the human and bovine MARCKS RNAs (75) suggests that these sequences may play a regulatory role, possibly in mRNA stability. Although its function is unknown, MARCKS pro-

tein localizes to substratum contact points in macrophages in physical association with vinculin, talin, and cytoskeletal actin (65, 78). MARCKS protein also binds to calmodulin with high affinity and inhibits calmodulin-mediated activation of phosphodiesterase (27, 55). This interaction is disrupted by protein kinase C-mediated MARCKS phosphorylation. MARCKS-regulated interaction with calmodulin is of particular interest in light of the role of calmodulin in lymphocyte apoptosis (54) and the ability of EBV or LMP 1 to protect cells from apoptosis (35). MARCKS may be a mediator of the anti-apoptotic effects of EBV infection.

Annexin VI is a  $\text{Ca}^{2+}$  binding protein of the lipocortin family (18) and is phosphorylated in response to growth factor stimulation (43). It may associate with CD21 (6). In vitro membrane reconstitution studies indicate that annexin VI may regulate the release of  $\text{Ca}^{2+}$  from intracellular stores (34). Annexin VI is expressed only in mantle zone B cells and is not detectable in GC cells (15).

Recent experiments indicate that annexin VI plays a critical role in the formation and budding of clathrin-coated pits by a process which may be triggered by specific phosphorylation (51). These findings are of particular significance since cathepsin H and serglycin may also be intracellular vesicle constituents. Cathepsin H is a lysosomal cysteine protease (9), whereas serglycin is a core protein of proteoglycans. Although not previously known to be expressed in lymphocytes, serglycin is stored in granulocyte secretory granules, where it may neutralize hydrolytic enzymes (45, 47).

CD44 binds hyaluronic acid (4) and is the lymphocyte homing receptor for high endothelial venules. Its expression increases following anti-Ig stimulation of murine B cells (13). In contrast with other EBV-induced genes, high-level CD44 expression in vivo is observed primarily in germinal-center B lymphocytes (24). CD44 may associate with the lymphocyte cytoskeleton via an ankyrinlike molecule (42). Transfection studies with Daudi and BL41 cell lines indicate that LMP 1 is responsible for CD44 induction (85).

The most significant outcome of this study is the discovery of the first G protein-coupled peptide receptors expressed in lymphocytes exclusively (as with EBI 1) or predominantly (as with EBI 2). Both genes are expressed at high levels in EBV(+) BL cells and EBV-transformed lymphoblastoid cell lines but are expressed at low or undetectable levels in two different EBV(-) BL lines. Expression of neither gene is entirely EBV specific, and EBI 1 and EBI 2 are likely to function normally as tissue-specific mediators of polypeptide cytokine effects. EBI 1 and EBI 2 RNAs are present in PBMCs at levels comparable to their levels in lymphoblastoid cell lines; they are also detected in RNA from unfractionated tonsil tissue, which consists mostly of B lymphocytes. The much higher EBI 2 RNA level in B-lymphocyte tissues and cell lines than in phytohemagglutinin-stimulated T cells and the T-cell lines Jurkat, HSB-2, and Molt-4 is evidence that EBI 2 expression in vivo is predominantly B- rather than T-lymphocyte restricted. An intermediate level of EBI 2 RNA was observed in HL60 and U937 cell lines and in pulmonary tissue, suggesting that EBI 2 may also be expressed in monocytes, granulocytes, and pulmonary tissue in vivo. In contrast, EBI 1 is expressed in B- and T-lymphocyte lines but not in nonlymphoid tissues or cell lines; it thus appears to be entirely lymphocyte restricted. The level of EBI 1 RNA in phytohemagglutinin-stimulated peripheral blood T cells and in T-cell lines indicates that both B and T lymphocytes may contribute to the overall expression observed in unfractionated PBMC, tonsil, and spleen

cell RNA preparations. Experiments are now in progress to delineate the roles of EBI 1 and EBI 2 in normal B- and T-lymphocyte development and immune responses.

The relatively high EBI 1 and EBI 2 mRNA levels in PBMCs, spleen tissue, and, to a lesser extent, tonsil tissue is surprising in light of the low levels in BL cells. EBI 1 and EBI 2 expression may be restricted to particular stages of lymphocyte differentiation or activation. EBV(-) BL cells may correspond to a differentiation state in which expression of both genes is characteristically low. In latent EBV infection, EBV gene products may act individually or in concert to activate expression or to maintain high levels of expression in host cells which already transcribe EBI 1 and EBI 2. Preliminary data indicate that EBI 1 is induced in EBV(-) BL cells converted to LMP 1 or EBNA 2 expression by single-gene transfer. EBI 2 expression may be specifically induced by EBNA 2 or EBNA LP since expression is up-regulated in BL41 cells transfected with an EBNA LP and EBNA 2 expression vector.

The extent of EBI 1 and EBI 2 homology to G protein-coupled peptide receptors makes it probable that EBI 1 and EBI 2 are receptors which transduce ligand-binding signals through heterotrimeric GTP-binding proteins (G proteins). Homologies between EBI 1 and the high- and low-affinity IL-8 receptors are particularly striking and are apparent at both the nucleotide and amino acid levels. In fact, EBI 1 is the closest known homolog of the IL-8 receptors. The neuropeptide Y receptor type 2, for which only the bovine form has thus far been cloned, also exhibits a high degree of homology to these proteins (64). These four proteins appear to constitute a closely related subfamily within the superfamily of G protein-coupled receptors. EBI 2 exhibits more distant homology to these proteins and appears to be most closely related to the thrombin receptor.

We have identified a previously unrecognized, highly conserved G protein-coupled receptor motif at the junction of the third transmembrane domain and second intracellular loop. This motif, (A/S)-(I/V)-D-R-(Y/F)-X-X-X-X, where X represents hydrophobic residues, is characteristic of even distantly related G protein-coupled receptors, including photoreceptor opsins and receptors from phylogenetically divergent species such as *Drosophila* species. The motif is not present in other proteins. The restricted presence of this sequence in G protein-coupled receptors is most consistent with an important role in G protein-coupled receptor function. This region is implicated in receptor interaction with G proteins (48). The sequence includes five continuous hydrophobic amino acids, and ligand binding may alter the disposition of the hydrophobic portion of this sequence with respect to the adjacent plasma membrane, effecting changes which modulate G protein interaction.

Ligands for EBI 1 or EBI 2 are likely to be polypeptide cytokines since EBI 1 and EBI 2 are most closely related to G protein-coupled receptors which have polypeptide ligands. Further, a third transmembrane domain aspartate residue is highly conserved among G protein-coupled biogenic amine receptors but is absent from EBI 1 and EBI 2, excluding membership in that family (73). The close similarity between EBI 1 and the IL-8 receptors is evidence that the EBI 1 ligand is a polypeptide proinflammatory "intercrine" factor similar to ACT-2, GRO/MGSA or RANTES, or IL-8 (63).

The expected action of EBI 1 and EBI 2 is through G proteins and secondary messenger pathways by the activation of effector molecules such as adenylyl cyclase, cyclic AMP phosphodiesterase, phospholipase C, or various ion

channels (20). In general, G protein-coupled peptide receptors regulate specialized functions of target cells, such as secretion of hormones in endocrine cells, membrane depolarization in neural cells, or chemotactic migration and activation of phagocytic cells. Ligand binding may also alter growth properties. Expression of the serotonin 1c receptor in immortalized rodent fibroblasts results in ligand-dependent oncogenic transformation (41). The melanoma growth-stimulatory activity protein (MGSA) binds to a G protein-coupled receptor and supports melanoma cell growth. MGSA can compete with IL-8 for binding to the IL-8 receptor, suggesting that the MGSA receptor may be closely related to the IL-8 receptors (58).

Indirect evidence indicates that a lymphocyte G protein-coupled receptor may affect phospholipase C activity and EBI 1 or EBI 2 may be the receptor that interacts in this pathway. Nonhydrolyzable GTP analogs constitutively activate both G proteins and lymphocyte polyphosphoinositide breakdown by phospholipase C (25, 33). Further, some experiments have demonstrated constitutive inhibition of phospholipase C activation by pertussis toxin, which blocks G proteins by ADP-ribosylation of their alpha subunits (25, 33, 57). Moreover, a G protein isoform regulates phospholipase C activity in brain tissue (69).

The finding that EBV induces these two putative G protein-coupled peptide receptors is also of interest in light of the recent findings that human cytomegalovirus and herpesvirus saimiri have incorporated homologs to G protein-coupled receptors into their genomes (60). Cytomegalovirus has three such genes (14). This virus is unusual among herpesviruses in its transient stimulation of cell DNA synthesis early in lytic replication and in establishing infection in precursor cells in bone marrow (52). Herpesvirus saimiri is a New World primate herpesvirus and is the herpesvirus most closely related to the EBV group of Old World primate lymphotropic herpesviruses (1). Herpesvirus saimiri can transform human T lymphocytes in vitro and can produce tumors in New World primates (7). The role of the G protein-coupled receptor homolog in herpesvirus saimiri infection has not been investigated. The finding that EBV induces G protein-coupled receptors and that cytomegalovirus and herpesvirus saimiri have incorporated G protein-coupled receptors into their genomes is compatible with the hypothesis that these G protein-coupled receptors mediate similar functions for these herpesviruses. However, comparison of the cytomegalovirus and herpesvirus saimiri homologs with EBI 1 and EBI 2 and the G protein-coupled peptide receptors reveals significant differences between the cytomegalovirus or herpesvirus saimiri G protein-coupled receptor homologs and the G protein-coupled peptide receptor group (Fig. 2B).

The identification of 9 different EBV-induced mRNAs among the first 12 clones and of 5 new and different mRNAs among 6 additional clones in various stages of sequence determination is evidence indicating that a larger group of EBV-induced genes can be identified by this approach. Other novel B-lymphocyte genes which may encode mediators of B-lymphocyte growth, differentiation, or activation or of EBV-induced growth transformation are likely to be identified.

#### ACKNOWLEDGMENTS

Fred Wang, Tom Tedder, Abul Abbas, and Alan Aderem contributed advice, and Lisa Boehmer provided assistance.

This research was supported by grant CA47006 from the National Cancer Institute of the U.S. Public Health Service. M.B. was a

Physician Scientist Awardee (grant 5K11CA01341) of the National Cancer Institute of the U.S. Public Health Service.

#### REFERENCES

1. Albrecht, J.-C., J. Nicholas, D. Biller, K. R. Cameron, B. Biesinger, C. Newman, S. Wittmann, M. A. Craxton, H. Coleman, B. Fleckenstein, and R. W. Honess. 1992. Primary structure of the herpesvirus saimiri genome. *J. Virol.* 66:5047-5058.
2. Alfieri, C., M. Birkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. *Virology*, 181:595-608. (Erratum, 185:946).
3. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* 215:403-410.
4. Aruffo, A., I. Stamenkovic, M. Melnick, C. B. Underhill, and B. Seed. 1990. CD44 is the principal cell surface receptor for hyaluronate. *Cell* 61:1303-1313.
5. Baichwal, V. R., and B. Sugden. 1988. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. *Oncogene* 2:461-467.
6. Barel, M., A. Gauffre, F. Lyamani, A. Fiandino, J. Hermann, and R. Frade. 1991. Intracellular interaction of EBV/C3d receptor (CR2) with p68, a calcium-binding protein present in normal but not in transformed B lymphocytes. *J. Immunol.* 147:1286-1291.
7. Biesinger, B., I. Muller-Fleckenstein, B. Simmer, G. Lang, S. Wittmann, E. Platzer, R. C. Desrosiers, and B. Fleckenstein. 1992. Stable growth transformation of human T lymphocytes by herpesvirus saimiri. *Proc. Natl. Acad. Sci. USA* 89:3116-3119.
- 7a. Birkenbach, M., and A. Aderem. Unpublished observations.
8. Birkenbach, M., D. Liebowitz, F. Wang, J. Sample, and E. Kieff. 1989. Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. *J. Virol.* 63:4079-4084.
9. Bohley, P., and P. O. Seglen. 1992. Proteases and proteolysis in the lysosome. *Experientia* 48:151-157.
10. Boyd, A. W., K. C. Anderson, A. S. Freedman, D. C. Fisher, B. Slaughenhaupt, S. F. Schlossman, and L. M. Nadler. 1985. Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody. *J. Immunol.* 134:1516-1523.
11. Brooks, S. F., T. Herget, J. D. Erusalimsky, and E. Rozengurt. 1991. Protein kinase C activation potently down-regulates the expression of its major substrate, 80K, in Swiss 3T3 cells. *EMBO J.* 10:2497-2505.
12. Calender, A., M. Billaud, J. P. Aubry, J. Banchereau, M. Vuillaume, and G. M. Lenoir. 1987. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. *Proc. Natl. Acad. Sci. USA* 84:8060-8064.
13. Camp, R. L., T. A. Kraus, M. L. Birkeland, and E. Pure. 1991. High levels of CD44 expression distinguish virgin from antigen-primed B cells. *J. Exp. Med.* 173:763-766.
14. Chee, M. S., S. C. Satchwell, E. Preddie, K. M. Weston, and B. G. Barrell. 1990. Human cytomegalovirus encodes three G protein-coupled receptor homologues. *Nature (London)* 344:774-777.
15. Clark, D. M., S. E. Moss, N. A. Wright, and M. J. Crumpton. 1991. Expression of annexin VI (p68, 67 kDa-callectrin) in normal human tissues: evidence for developmental regulation in B- and T-lymphocytes. *Histochemistry* 96:405-412.
16. Cohen, J. I., F. Wang, and E. Kieff. 1991. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. *J. Virol.* 65:2545-2554.
17. Cordier, M., A. Calender, M. Billaud, U. Zimmer, G. Rousselet, O. Pavlish, J. Banchereau, T. Tursz, G. Bornkamm, and G. M. Lenoir. 1990. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. *J. Virol.* 64:1002-1013.
18. Crumpton, M. R., R. J. Owens, N. F. Totty, S. E. Moss, M. D. Waterfield, and M. J. Crumpton. 1988. Primary structure of the

- human, membrane-associated Ca<sup>2+</sup>-binding protein p68 a novel member of a protein family. *EMBO J.* 7:21-27. (Erratum, 7:1914.)
19. Curnow, K., I. Pascoe, and P. White. 1992. Genetic analysis of the human type 1 angiotensin II receptor. *Mol. Endocrinol.* 6:1113-1118.
  20. Dohlman, H. G., J. Thorner, M. G. Caron, and R. J. Lefkowitz. 1991. Model systems for the study of seven-transmembrane-segment receptors. *Annu. Rev. Biochem.* 60:653-688.
  21. Ehlin-Henriksson, B., A. Manneborg-Sandlund, and G. Klein. 1987. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups. *Int. J. Cancer* 39:211-218.
  22. Fahraeus, R., A. Jansson, A. Ricksten, A. Sjöblom, and L. Rymo. 1990. Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. *Proc. Natl. Acad. Sci. USA* 87:7390-7394.
  23. Favrot, M. C., O. Maritz, T. Suzuki, M. Cooper, I. Phillip, T. Phillip, and G. Lenoir. 1986. EBV-negative and -positive Burkitt cell lines variably express receptors for B-cell activation and differentiation. *Int. J. Cancer* 38:901-906.
  24. Fyfe, G., T. J. Cebra, E. Mustain, J. M. Davie, C. D. Alley, and M. H. Nahm. 1987. Subpopulations of B lymphocytes in germinal centers. *J. Immunol.* 139:2187-2194.
  25. Gold, M. R., J. P. Jakway, and A. L. DeFranco. 1987. Involvement of a guanine-nucleotide-binding component in membrane IgM-stimulated phosphoinositide breakdown. *J. Immunol.* 139:3604-3613.
  26. Gordon, J., L. Walker, G. Guy, G. Brown, M. Rowe, and A. Rickinson. 1986. Control of human B-lymphocyte replication. II. Transforming Epstein-Barr virus exploits three distinct viral signals to undermine three separate control points in B-cell growth. *Immunology* 58:591-595.
  27. Graff, J. M., T. N. Young, J. D. Johnson, and P. J. Blackshear. 1989. Phosphorylation-regulated calmodulin binding to a prominent cellular substrate for protein kinase C. *J. Biol. Chem.* 264:21818-21823.
  28. Gregory, C. D., C. F. Edwards, A. Milner, J. Wiels, M. Lipinski, M. Rowe, T. Tursz, and A. B. Rickinson. 1988. Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus. *Int. J. Cancer* 42:213-220.
  29. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. *J. Gen. Virol.* 71:1481-1495.
  30. Gregory, C. D., T. Tursz, C. F. Edwards, C. Tetaud, M. Talbot, B. Caillou, A. B. Rickinson, and M. Lipinski. 1987. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. *J. Immunol.* 139:313-318.
  31. Guy, G. R., and J. Gordon. 1989. Epstein-Barr virus and a tumour-promoting phorbol ester use similar mechanisms in the stimulation of human B-cell proliferation. *Int. J. Cancer* 43:703-708.
  32. Harlan, D. M., J. M. Graff, D. J. Stumpo, R. L. J. Eddy, T. B. Shows, J. M. Boyle, and P. J. Blackshear. 1991. The human myristoylated alanine-rich C kinase substrate (MARCKS) gene (MACS). Analysis of its gene product, promoter, and chromosomal localization. *J. Biol. Chem.* 266:14399-14405.
  33. Harnett, M. M., and G. G. Klaus. 1988. G protein coupling of antigen receptor-stimulated polyphosphoinositide hydrolysis in B cells. *J. Immunol.* 140:3135-3139.
  34. Hazarika, P., M. A. Kaetzel, A. Sheldon, N. J. Karin, S. Fleischer, T. E. Nelson, and J. R. Dedman. 1991. Annexin VI is associated with calcium-sequestering organelles. *J. Cell. Biochem.* 46:78-85.
  35. Henderson, S., M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff, and A. Rickinson. 1991. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. *Cell* 65:1107-1115.
  36. Henle, G., W. Henle, and V. Diehl. 1968. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. *Proc. Natl. Acad. Sci. USA* 59:94-101.
  37. Higgins, D. G., and P. M. Sharp. 1988. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. *Gene* 73:237-244.
  38. Holmes, W. E., J. Lee, W. J. Kuang, G. C. Rice, and W. I. Wood. 1991. Structure and functional expression of a human interleukin-8 receptor. *Science* 253:1278-1280.
  39. Hornbeck, P., H. Nakabayashi, B. J. Fowlkes, W. E. Paul, and D. Kligman. 1989. A major myristylated substrate of protein kinase C and protein kinase C itself are differentially regulated during murine B- and T-lymphocyte development and activation. *Mol. Cell. Biol.* 9:3727-3735.
  40. Hornbeck, P., and W. E. Paul. 1986. Anti-immunoglobulin and phorbol ester induce phosphorylation of proteins associated with the plasma membrane and cytoskeleton in murine B lymphocytes. *J. Biol. Chem.* 261:14817-14824.
  41. Julius, D., T. J. Livelli, T. M. Jessell, and R. Axel. 1989. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. *Science* 244:1057-1062.
  42. Kalomiris, E. L., and L. Y. Bourguignon. 1988. Mouse T lymphoma cells contain a transmembrane glycoprotein (GP85) that binds ankyrin. *J. Cell Biol.* 106:319-327.
  43. Kenton, P., P. M. Johnson, and P. D. Webb. 1989. The phosphorylation of p68, a calcium-binding protein associated with the human syncytiotrophoblast submembranous cytoskeleton, is modulated by growth factors, activators of protein kinase C and cyclic AMP. *Biochim. Biophys. Acta* 1014:271-281.
  44. Kieff, E., and D. Liebowitz. 1990. Epstein-Barr virus and its replication, p. 1889-1920. In B. N. Fields and D. M. Knipe (ed.), its replication, Virology, 2nd ed. Raven Press, New York.
  45. Kjellen, L., and U. Lindahl. 1991. Proteoglycans: structures and interactions. *Annu. Rev. Biochem.* 60:443-475.
  46. Kautson, J. C. 1990. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. *J. Virol.* 64:2530-2536.
  47. Kolset, S. O., and J. T. Gallagher. 1990. Proteoglycans in haemopoietic cells. *Biochim. Biophys. Acta* 1032:191-211.
  48. König, B., A. Arendt, J. H. McDowell, M. Kahlert, P. A. Hargrave, and K. P. Hoffman. 1989. Three cytoplasmic loops of rhodopsin interact with transducin. *Proc. Natl. Acad. Sci. USA* 86:6878-6882.
  49. Kozak, M. 1991. Structural features in eukaryotic mRNAs that modulate the initiation of translation. *J. Biol. Chem.* 266:19867-19870.
  50. Liebowitz, D., R. Kopan, E. Fuchs, J. Sample, and E. Kieff. 1987. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. *Mol. Cell. Biol.* 7:2299-2308.
  51. Lin, H. S., T. C. Sudhof, and R. G. W. Anderson. 1992. Annexin VI is required for budding of clathrin-coated pits. *Cell* 70:283-291.
  52. Maciejewski, J. P., E. E. Bruening, R. E. Donahue, E. S. Mocarski, N. S. Young, and S. C. St. Jeor. 1992. Infection of hematopoietic cells by human cytomegalovirus. *Blood* 80:170-178.
  53. Matsumoto, A., J. Kopicky-Bird, R. Carter, D. Tuveson, T. Tedder, and D. Fearon. 1991. Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte containing complement receptor type 2 and CD19. *J. Exp. Med.* 173:55-64.
  54. McConkey, D. J., P. Nicotera, P. Hartzell, G. Bellomo, A. H. Wyllie, and S. Orrenius. 1989. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca<sup>2+</sup> concentration. *Arch. Biochem. Biophys.* 269:365-370.
  55. McIlroy, B. K., J. D. Walters, P. J. Blackshear, and J. D. Johnson. 1991. Phosphorylation-dependent binding of a synthetic MARCKS peptide to calmodulin. *J. Biol. Chem.* 266:4959-4964.
  56. Miller, G. 1990. Epstein-Barr virus, p. 1921-1958. In B. N. Fields, and D. M. Knipe (ed.), Virology, 2nd ed. Raven Press, New York.
  57. Monroe, J. G., and S. Halder. 1989. Involvement of a specific guanine nucleotide binding protein in receptor immunoglobulin stimulated inositol phospholipid hydrolysis. *Biochim. Biophys.*

- Acta 1013:273-278.
58. Moser, B., C. Schumacher, T. V. von Tschärner, L. I. Clark, and M. Baggiolini. 1991. Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. *J. Biol. Chem.* 266:10666-10671.
  59. Murphy, P. M., and H. Tiffany. 1991. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. *Science* 253:1280-1283.
  60. Nicholas, J., K. R. Cameron, and R. W. Honess. 1992. Herpesvirus saimiri encodes homologues of G protein-coupled receptors and cyclins. *Nature (London)* 355:362-365.
  61. Nilsson, K., and G. Klein. 1982. Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. *Adv. Cancer Res.* 37:319-380.
  62. Nilsson, K., G. Klein, W. Henle, and G. Henle. 1971. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. *Int. J. Cancer* 8:443-450.
  63. Oppenheim, J. J., C. O. Zachariae, N. Mukaida, and K. Matsushima. 1991. Properties of the novel proinflammatory supergene "intercrine" cytokine family. *Annu. Rev. Immunol.* 9:617-648.
  64. Rimland, J., W. Xin, P. Sweetnam, K. Saijoh, E. Nestler, and R. Ovman. 1991. Sequence and expression of a neuropeptide Y receptor cDNA. *Mol. Pharmacol.* 40:869-875.
  65. Rosen, A., K. F. Keenan, M. Thelen, A. C. Nairn, and A. Aderem. 1990. Activation of protein kinase C results in the displacement of its myristoylated, alanine-rich substrate from punctate structures in macrophage filopodia. *J. Exp. Med.* 172:1211-1215.
  66. Rowe, M., C. M. Rooney, C. F. Edwards, G. M. Lenoir, and A. B. Rickinson. 1986. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. *Int. J. Cancer* 37:367-373.
  67. Rowe, M., C. M. Rooney, A. B. Rickinson, G. M. Lenoir, H. Rupani, D. J. Moss, H. Stein, and M. A. Epstein. 1985. Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. *Int. J. Cancer* 35:435-441.
  68. Rowe, M., D. T. Rowe, C. D. Gregory, L. S. Young, P. J. Farrell, H. Rupani, and A. B. Rickinson. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. *EMBO J.* 6:2743-2751.
  69. Smrcka, A. V., J. R. Hepler, K. O. Brown, and P. C. Sternweis. 1991. Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq. *Science* 251:804-807.
  70. Spira, G., P. Aman, N. Koide, G. Lundin, G. Klein, and K. Hall. 1981. Cell-surface immunoglobulin and insulin receptor expression in an EBV-negative lymphoma cell line and its EBV-converted sublines. *J. Immunol.* 126:122-126.
  71. Sreedhara, S., A. Robichon, and K. Peterson. 1991. Cloning and expression of the human vaso active intestinal peptide receptor. *Proc. Natl. Acad. Sci. USA* 88:4986-4990.
  72. Stashenko, P., L. M. Nadler, R. Hardy, and S. F. Schlossman. 1981. Expression of cell surface markers after human B lymphocyte activation. *Proc. Natl. Acad. Sci. USA* 78:3848-3852.
  73. Strader, C. D., I. S. Sigal, M. R. Candelore, E. Rands, W. S. Hill, and R. A. Dixon. 1988. Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. *J. Biol. Chem.* 263:10267-10271.
  74. Strosberg, A. D. 1991. Structure/function relationship of proteins belonging to the family of receptors coupled to GTP-binding proteins. *Eur. J. Biochem.* 916:1-10.
  75. Stumpo, D. J., J. M. Graff, K. A. Albert, P. Greengard, and P. J. Blackshear. 1989. Molecular cloning, characterization, and expression of a cDNA encoding the "80- to 87-kDa" myristoylated alanine-rich C kinase substrate: a major cellular substrate for protein kinase C. *Proc. Natl. Acad. Sci. USA* 86:4012-4016.
  76. Suzuki, T., S. K. Sanders, J. L. Butler, G. L. Gartland, K. Komiyama, and M. D. Cooper. 1986. Identification of an early activation antigen (Bac-1) on human B cells. *J. Immunol.* 137:1208-1213.
  77. Tanner, J., J. Weis, D. Fearon, Y. Whang, and E. Kieff. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. *Cell* 50:203-213.
  78. Thelen, M., A. Rosen, A. C. Nairn, and A. Aderem. 1991. Regulation by phosphorylation of reversible association of a myristoylated protein kinase C substrate with the plasma membrane. *Nature (London)* 351:320-322.
  79. Thorley-Lawson, D. A., L. M. Nadler, A. K. Bhan, and R. T. Schooley. 1985. BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein-Barr virus. *J. Immunol.* 134:3007-3012.
  80. Thorley-Lawson, D. A., S. L. Swendeman, C. M. Edson. 1986. Biochemical analysis suggests distinct functional roles for the BLAST-1 and BLAST-2 antigens. *J. Immunol.* 136:1745-1751.
  81. Vu, T. K., D. T. Hung, V. I. Wheaton, and S. R. Coughlin. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. *Cell* 64:1057-1068.
  82. Wang, D., D. Liebowitz, and E. Kieff. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. *Cell* 43:831-840.
  83. Wang, D. D. Liebowitz, and E. Kieff. 1988. The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. *J. Virol.* 62:2337-2346.
  84. Wang, D., D. Liebowitz, F. Wang, C. Gregory, A. Rickinson, R. Larson, T. Springer, and E. Kieff. 1988. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. *J. Virol.* 62:4173-4184.
  85. Wang, F., C. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. *J. Virol.* 64:2309-2318.
  86. Wang, F., C. D. Gregory, M. Rowe, A. B. Rickinson, D. Wang, M. Birkenbach, H. Kikutani, T. Kishimoto, and E. Kieff. 1987. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. *Proc. Natl. Acad. Sci. USA* 84:3452-3456.
  87. Wang, F., S. F. Tsang, M. G. Kurilla, J. I. Cohen, and E. Kieff. 1990. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. *J. Virol.* 64:3407-3416.
  88. Weis, J., T. Tedder, and D. Fearon. 1984. Identification of a 145,000 M<sub>r</sub> membrane protein as the C3d receptor (CR2) of human B lymphocytes. *Proc. Natl. Acad. Sci. USA* 81:881-885.
  89. Yamada, Y., S. Post, K. Wang, H. Tager, G. Bell, and S. Seino. 1992. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. *Proc. Natl. Acad. Sci. USA* 89:251-255.

# JOURNAL OF VIROLOGY

VOLUME 67 • APRIL 1993 • NUMBER 4

**Arnold J. Levine, Editor in Chief (1994)**  
Princeton University  
Princeton, N.J.

**John M. Coffin, Editor (1996)**  
Tufts University Medical School  
Boston, Mass.

**Ronald C. Desrosiers, Editor (1998)**  
Harvard Medical School  
Boston, Mass.

**Bernard N. Fields, Editor (1993)**  
Harvard Medical School  
Boston, Mass.

**Stephen P. Goff, Editor (1994)**  
Columbia University  
New York, N.Y.

**Peter M. Howley, Editor (1993)**  
National Cancer Institute  
Bethesda, Md.

**Robert A. Lamb, Editor (1997)**  
Northwestern University  
Evanston, Ill.

**Michael B. A. Oldstone, Editor (1993)**  
Scripps Clinic & Research Foundation  
La Jolla, Calif.

**Carol Prives, Editor (1996)**  
Columbia University  
New York, N.Y.

**Vincent R. Racaniello, Editor (1997)**  
Columbia University  
New York, N.Y.

**Thomas E. Shenk, Editor (1994)**  
Princeton University  
Princeton, N.J.

## EDITORIAL BOARD

Rafi Ahmed (1994)  
James Alwine (1994)  
Carl C. Baker (1994)  
Amiya K. Banerjee (1993)  
Kenneth I. Berns (1994)  
Joseph B. Bolen (1994)  
Thomas J. Braciale (1994)  
John Brady (1994)  
Thomas R. Broker (1995)  
Michael J. Buchmeier (1995)  
Robert Callahan (1994)  
Barrie J. Carter (1993)  
Mark Challenge (1995)  
Irvin S. Y. Chen (1993)  
Bruce W. Chesebro (1994)  
Donald M. Coen (1995)  
Gary H. Cohen (1994)  
Charles N. Cole (1995)  
Peter L. Collins (1994)  
Richard W. Compans (1993)  
Richard C. Condit (1995)  
Neal G. Copeland (1995)  
Richard J. Courtney (1995)  
Clyde S. Crumpacker II (1994)  
Bryan R. Cullen (1993)  
Thomas Curran (1994)  
Samuel Dales (1994)  
Daniel DiMaio (1994)  
Walter Doerfler (1995)  
Elvera Ehrenfeld (1995)  
Robert N. Eisenman (1994)  
John Elder (1993)  
Michael Emerman (1995)  
Suzanne U. Emerson (1995)  
Lynn W. Enquist (1994)  
Mary K. Estes (1995)  
Hung Fan (1994)  
Ellen Fanning (1994)  
Bernard Fleckenstein (1993)  
S. Jane Flint (1993)  
William R. Folk (1994)

Paul D. Friesen (1994)  
Denise A. Galloway (1995)  
Don Ganem (1994)  
Costa P. Georgopoulos (1995)  
Joseph C. Glorioso (1995)  
Harry B. Greenberg (1995)  
Hidesaburo Hanafusa (1995)  
Ed Harlow (1993)  
Ari H. Helenius (1993)  
Virginia S. Hinshaw (1993)  
James M. Hogle (1994)  
John J. Holland (1993)  
Kathryn V. Holmes (1994)  
Nancy Hopkins (1995)  
Alice S. Huang (1993)  
Stephen H. Hughes (1994)  
Eric Hunter (1993)  
Tony Hunter (1995)  
Nancy A. Jenkins (1995)  
Richard A. Katz (1993)  
Jack D. Keene (1994)  
Thomas J. Kelly (1994)  
Elliott Kieff (1993)  
Karl Kirkegaard (1993)  
Geoffrey R. Kitchingman (1995)  
Daniel F. Klessig (1994)  
David M. Knipe (1994)  
Hsing-Jien Kung (1993)  
Ching-Juh Lai (1993)  
Michael Lai (1994)  
Jonathan Leis (1994)  
Norman L. Letvin (1995)  
Maxine Linial (1994)  
David M. Livingston (1994)  
Douglas R. Lowy (1995)  
James L. Manley (1995)  
Malcolm A. Martin (1995)  
William S. Mason (1994)  
Michael B. Mathews (1994)  
A. Dusty Miller (1994)  
Lois K. Miller (1994)

Edward S. Mocarski (1993)  
Peter Model (1995)  
Bernard Moss (1995)  
Richard W. Moyer (1995)  
James Mullins (1993)  
Brian R. Murphy (1994)  
Nicholas A. Muzyczka (1993)  
Gerald Myers (1995)  
Opendra Narayan (1994)  
Neal Nathanson (1993)  
Jay A. Nelson (1994)  
Joseph R. Nevins (1994)  
Dennis O'Callaghan (1995)  
Peter Palese (1994)  
Enzo Paoletti (1994)  
Takis Papas (1993)  
J. Thomas Parsons (1995)  
David J. Pintel (1995)  
Abraham Pinter (1994)  
James Pipas (1993)  
Lewis I. Pizer (1993)  
Nancy Raab-Traub (1993)  
Arnold B. Rabson (1993)  
R. Frank Ramig (1994)  
Dan S. Ray (1995)  
Alan Rein (1993)  
Solon L. Rhode (1995)  
William S. Robinson (1995)  
Bernard Roizman (1994)  
John K. Rose (1994)  
Craig Rosen (1993)  
Naomi Rosenberg (1995)  
Roland R. Rueckert (1994)  
Norman P. Salzman (1993)  
Charles E. Samuel (1995)  
Richard Jude Samulski (1995)  
Dorothea L. Sawicki (1994)  
Priscilla A. Schaffer (1993)  
Heinz Schaller (1995)  
Sondra Schlesinger (1995)  
Robert J. Schneider (1994)

Manfred H. Schubert (1993)  
Bartholomew M. Sefton (1994)  
Bert L. Semler (1995)  
David A. Shafritz (1994)  
Yosef Shaul (1995)  
Saul J. Silverstein (1994)  
Daniel T. Simmons (1995)  
Anna Marie Skalka (1993)  
Joseph Sodarski (1995)  
Nahum Sonenberg (1993)  
Arne Stenlund (1995)  
Mark F. Stinski (1995)  
James Strauss (1993)  
Bill Sugden (1993)  
Jesse Summers (1995)  
Ron Swanstrom (1993)  
Peter J. Tattersall (1995)  
John M. Taylor (1993)  
Howard M. Temin (1994)  
Mary J. Tevethia (1993)  
Satvir S. Tevethia (1994)  
David A. Thorley-Lawson (1994)  
Paula Traktman (1995)  
Philip N. Tschlis (1995)  
Kenneth L. Tyler (1994)  
Inder Verma (1995)  
Luis V. Villarreal (1994)  
Peter K. Vogt (1993)  
Edward K. Wagner (1995)  
Robert G. Webster (1993)  
Raymond M. Welsh (1994)  
Gail Wertz (1994)  
J. Lindsay Whitton (1995)  
Reed B. Wickner (1994)  
John W. Wills (1995)  
Eckard Wimmer (1994)  
Flossie Wong-Staal (1993)  
Moshe Yaniv (1995)  
Charles Hamish Young (1995)  
Harald zur Hausen (1995)

**Barbara H. Iglewski, Chairman, Publications Board**

**Linda M. Illig, Director, Journals**

**Judith Nedrow, Production Editor**

The *Journal of Virology*, a publication of the American Society for Microbiology (ASM), 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171, is devoted to the dissemination of fundamental knowledge concerning viruses of bacteria, plants, and animals. Investigators are invited to submit reports of original research in all areas of basic virology, including biochemistry, biophysics, genetics, immunology, morphology, physiology, and pathogenesis and immunity. Instructions to authors are published in the January issue each year; reprints are available from the editors and the Journals Division. The *Journal* is issued monthly, one volume per year. The nonmember print subscription prices are \$362 (U.S.) (Canadians add 7% GST) and \$432 (other countries) per year; single copies are \$40 (Canadians add 7% GST). The member print subscription prices are \$81 (U.S.) (Canadians add 7% GST) and \$97 (other countries) per year; single copies are \$10 (Canadians add 7% GST). For prices of CD-ROM versions, contact the Subscriptions Unit, ASM. Correspondence relating to subscriptions, defective copies, missing issues, and availability of back issues should be directed to the Subscriptions Unit, ASM. Correspondence relating to reprint orders should be directed to the Reprint Order Unit, ASM; and correspondence relating to disposition of submitted manuscripts, proofs, and general editorial matters should be directed to the Journals Division, American Society for Microbiology, 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171. Phone: (202) 737-3600.

Claims for missing issues from residents of the United States, Canada, and Mexico must be submitted within 3 months of publication of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing because of failure to report an address change or for issues "missing from files" will not be allowed.

Second-class postage paid at Washington, DC 20005, and at additional mailing offices.

POSTMASTER: Send address changes to *Journal of Virology*, ASM, 1325 Massachusetts Ave., N.W., Washington, DC 20005-4171.

Made in the U.S.A. Printed on acid-free paper.

Copyright © 1993, American Society for Microbiology.

All Rights Reserved.

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per-copy fee through the Copyright Clearance Center, 27 Congress St., Salem, MA 01970, for copying beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

ISSN:0022-538X

CODEN: JOVIMM

日本: 価格は外貨表示とは関係なく円建。

1305 Linden Drive  
Madison, WI 53706